The GLP-1 stock nobody is pricing in isn’t a drugmaker

$LLY printed $19.8B in Q1 revenue (+55% YoY) as GLP-1 demand chemically reshapes the same market $AMZN's pharmacy is quietly capturing.

$HIMS absorbed a $92M Q1 loss exiting compounded GLP-1s but raised 2026 revenue guidance to $3B with a 2030 target of $6.5B.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Amazon didn't make the cut. Grab the names FREE today.

Scott Galloway and Ed Elson laid out the math on Prof G Markets and it should make every fast food shareholder uneasy: roughly 30 million Americans, about 1 in 8 US adults, are now on GLP-1s, and the drugs are reducing fast food's addressable market by an estimated 27-30%. This is structural, not cyclical: appetite, the literal raw material of the drive-thru economy, is being chemically suppressed at scale. Below are five US-listed stocks positioned on the winning side of that trade, ranked so the most surprising name leads and the punchline lands at #5.

The GLP-1 trade is as much about who puts the pen in the patient's hand on a Tuesday afternoon as it is about who makes the molecule. Amazon (NASDAQ:AMZN) quietly turned itself into the most frictionless GLP-1 fulfillment channel in the country while everyone was busy debating AWS multiples. Amazon Pharmacy is expanding Same-Day delivery to nearly 4,500 US cities and towns by year-end, and the company just launched a 24/7 AI-powered personal health agent inside its main app. Whole Foods is in the same portfolio. So is Prime. The flywheel is already built; GLP-1 just gives it another lane.

The Q1 numbers say the underlying engine is accelerating, not slowing. Revenue hit $181.52B, AWS grew 28%, its fastest in 15 quarters, and CEO Andy Jassy said "unit growth in our Stores reached 15% (the highest since the tail end of covid lockdowns)". Shares are up only 3% year to date and just 9% over the past year, which means the pharmacy optionality is essentially free.

Amazon is the surprise leadoff. The obvious heavyweight comes next, and its quarterly print is genuinely difficult to argue with.

If GLP-1s are the new cigarettes (only in reverse, shrinking demand for everything calorically adjacent), then Eli Lilly (NYSE:LLY) is Philip Morris circa 1955. Mounjaro and Zepbound are the dominant injectables, and the FDA just approved Foundayo (orforglipron), the only approved GLP-1 pill that can be taken any time of day, without food and water restrictions. Pills travel better than pens. Pills scale internationally. Pills crush stigma. This is the catalyst that opens the back half of the decade.

Q1 FY26 was a statement quarter. Revenue came in at $19.80 billion, up 55.5% YoY, with EPS of $8.55 beating the $6.79 consensus. Inside the headline number, Mounjaro printed $8.66 billion (+125% YoY) and Zepbound printed $4.16 billion (+80% YoY). CEO David Ricks said "Foundayo will meaningfully expand the number of people who can benefit from GLP-1s."

Reddit caught on late. LLY sentiment surged from neutral (52) in mid-May to very bullish (82-88) by early June. Shares are up 42% over the past year. Next earnings: August 3, 2026. There is one other GLP-1 incumbent, and its stock chart looks like the opposite of Lilly's.

The original GLP-1 pioneer has been left for dead by the market. Novo Nordisk (NYSE:NVO) is down 44% over the past year while Lilly ripped higher. That dislocation is the trade. Novo just launched its own oral GLP-1, Wegovy pill, on January 5, 2026, and the company says it is already used by more than one million patients with over 200,000 weekly US prescriptions. Wegovy HD, approved in March 2026, delivers ~20.7% weight loss. The franchise keeps compounding; only the multiple has cracked.

The Wegovy pill alone generated $2.26 billion in its debut quarter, while Wegovy injectable did $18.24 billion (+12%). Management raised FY26 adjusted sales growth guidance to -4% to -12% CER from -5% to -13%, and authorized a new DKK 15B share buyback. CEO Mike Doustdar said "Wegovy is driving a strong start to 2026... rapid adoption of Wegovy pill, the most efficacious GLP-1 tablet now used by more than one million patients since its January launch."

Retail is still hostile. NVO Reddit sentiment collapsed from neutral (48-53) in May to bearish (22-29) in early June. That is exactly the kind of crowd-positioning gap I look for. You buy Novo IF you believe the duopoly holds and the multiple re-rates as the pill ramps; you avoid it if you think Lilly's superiority data ends the story. The next stock on the list does not need you to pick a winner between them at all.

GLP-1 patients keep eating, just differently. Smaller portions, more protein, more produce, less processed garbage. That is the entire merchandising thesis of Sprouts Farmers Market (NASDAQ:SFM). The company sits inside a $290 billion health and wellness food-at-home market, has 483 stores in 25 states, and a long-term target of 1,000+ stores. While drive-thrus lose foot traffic, Sprouts is building the food rails for the post-Ozempic shopping cart.

Q1 FY26 had soft comps but the structural story kept compounding. Revenue was $2.329 billion (+4.15% YoY) with EPS of $1.71 beating the $1.67 estimate. Two numbers I keep coming back to: Sprouts Brand penetration climbed to 26% of sales from 23%, and ROIC hit 17.4%. CEO Jack Sinclair said "We continue to focus on accelerating customer engagement, foraging and discovery, building an advantaged supply chain, and expanding access to healthy food."

Shares are still down 46% over the past year on the comp slowdown, but up 9% year to date and 10% in the past week. Next earnings: August 3, 2026. The reset has likely already happened. Which leaves one final stock, and it is the most directly leveraged name on this list to the consumer side of GLP-1 distribution.

Hims & Hers Health (NYSE:HIMS) is the messiest name on the list and possibly the most asymmetric. The company just absorbed a brutal strategic pivot: out of compounded GLP-1s, into branded GLP-1 distribution. That cost real money in Q1, but it converts Hims from a regulatory bullseye into a long-duration consumer health platform riding the same wave as Lilly and Novo.

CEO Andrew Dudum said "2026 is a defining year for Hims & Hers. We're not just growing, we're pulling away from the field on our path to becoming the world's largest consumer health platform." Shares are down 50% over the past year, the analyst target sits at $26.61, and a former Netflix CFO just bought $1.2M of stock, which flipped r/wallstreetbets sentiment to 72 (bullish) on June 1. The next earnings report lands August 10, 2026.

The Prof G thesis is not subtle: GLP-1s are chemically resetting the addressable market of every business that sells calories on impulse. Lilly and Novo make the molecule, Hims puts it in the consumer's mailbox, Amazon owns the delivery rail and the next-gen pharmacy, and Sprouts feeds the patients who now plan every plate around protein and produce. The fast food incumbents have three earnings cycles to figure out a response. The capital is already moving. Position before the August prints, or read about it after.